Genomics Market: Emerging Technologies, Industry Trends, and Growth Opportunities
The Genomics Market is expanding rapidly as sequencing technologies become more accessible and genomic information becomes increasingly integrated into clinical decision-making. Sequencing is helping researchers and healthcare organizations investigate genetic variation, identify disease-associated mutations, and develop more targeted approaches to diagnosis and treatment.
Market Research Future reports that the global genomics market reached USD 30.15 billion in 2025 and is expected to reach USD 84.30 billion by 2035, expanding at a CAGR of 10.80% between 2026 and 2035.
Sequencing represents the largest technology category, accounting for 36.7% of the market in 2025. The segment includes both short-read and long-read sequencing platforms. Short-read systems continue to support high-throughput genomic analysis, while long-read technologies are gaining attention because they can identify structural variants, repeat expansions, and other genomic features that may be difficult to characterize using conventional approaches.
The development of long-read sequencing is particularly important for clinical genomics. Improved accuracy and expanding applications are supporting its use in gene-therapy research, rare-disease testing, and complex genetic analysis. Market Research Future projects long-read and single-molecule technologies to grow at a 12.8% CAGR through 2035.
Personalized medicine is another major growth area. Genomic testing allows healthcare providers and pharmaceutical companies to understand genetic differences that may influence disease risk, drug response, and treatment outcomes. The growing use of pharmacogenomics and companion diagnostics is increasing the importance of genomic information in therapeutic development.
The pharmaceutical and biotechnology sector is also investing heavily in genomics. Genomic data can support target identification, biomarker discovery, patient stratification, and clinical-trial development. As drug developers increasingly focus on precision therapies, genomic technologies are expected to become more closely integrated with pharmaceutical R&D.
Artificial intelligence is further changing genomic analysis. AI-powered systems can assist with variant interpretation, genomic data analysis, and identification of biologically relevant patterns within large datasets. The combination of AI and genomics could improve analytical efficiency while helping laboratories manage increasingly complex genomic information.
As sequencing costs continue to decline and genomic technologies become more accessible, adoption is expected to expand beyond specialized research institutions. Hospitals, diagnostic laboratories, pharmaceutical companies, and emerging healthcare markets are likely to contribute significantly to future growth.
